Prostate Cancer

Eligard to be launched in Germany

Published in Cancer Weekly, June 8th, 2004

Atrix Laboratories, Inc., (ATRX) announced that Eligard 7.5mg and Eligard 22.5mg (leuprolide acetate for injectable suspension) 1- and 3-month sustained release products were launched in Germany by Yamanouchi. Eligard is indicated for the palliative treatment of advanced prostate cancer.

"We are pleased to have Eligard competing in Germany, the third largest market in the world for this type of treatment," said David R. Bethune, chairman and chief executive officer at Atrix. "We look forward to other European approvals and launches over the next several years."

In early December 2003 and early January 2004, MediGene received marketing authorization...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-06-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry